Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line pemetrexed/carboplatin versus gemcitabine/carboplatin in advanced non-squamous NSCLC
ChiCTR-TRC-09000546Phase 2Completed
- Sponsor
- Dongguan People's Hospital
- Start
- Jul 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemetrexed, carboplatin and gemcitabine in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Dongguan People's Hospital. Primary endpoint: Overall response rate. Started Jul 2009; status: completed.
02
Drugs
pemetrexedcarboplatingemcitabine
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000546.